Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. (Nasdaq: CLRB) is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies. The company's proprietary Phospholipid Ether (PLE) platform technology enables selective delivery of therapeutic payloads directly to cancer cells by exploiting the elevated lipid raft content on malignant cell membranes. This precision approach supports development across multiple drug classes — including phospholipid drug conjugates (PDCs) — with a focus on advanced cancers where existing treatment options are inadequate. Cellectar's mission is to improve survival and quality of life for patients with advanced cancers by delivering well-tolerated therapies that minimize harm to healthy tissue. The company has received 3 SBIR/STTR awards from the Department of Health and Human Services and has established collaborations with Onconova Therapeutics and Orano Med for PDC development.